ClinicalTrials.gg
CompletedNCT06481488Updated Jan 16, 2025

A Study of E2086 in Healthy Adult Participants

A Phase 1 interventional study of E2086 and Placebo in Healthy Volunteers, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary purpose of the study is to evaluate the safety and tolerability following multiple ascending doses of E2086 in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Non-smoking, male or female, aged greater than or equal to (>=) 18 years to less than or equal to (\<=) 55 years (>=20 years to \<=55 years for Japanese participants) at the time of . To be considered non-smokers, participants must have discontinued smoking for at least 4 weeks before dosing
  2. Japanese participants must have been born in Japan of Japanese parents and Japanese grandparents, must have lived no more than 5 years outside of Japan, and must not have changed their lifestyle or habits, including diet, while living outside of Japan
  3. (BMI) >=18 to less than (\<) 30 kilogram per square meter (kg/m\^2) at screening only for Part A
  4. Reports regular bedtime, defined as the time the participant attempts to sleep, between 22:00 and midnight
  5. Reports regular waketime, defined as the time the participant gets out of bed for the day, between 05:00 and 10:00

Exclusion criteria

Exclusion Criteria:

  1. Females who are breastfeeding or pregnant at screening or baseline (as documented by a positive beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 international units per liter (IU/L) or equivalent units of ß-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the dose of study drug
  2. All females who are of : All females will be considered to be of childbearing potential unless they are (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (that is, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing)
  3. Males who have not had a successful vasectomy (confirmed azoospermia) or their female partners do not meet the criteria above (that is, not of childbearing potential) or practicing highly effective throughout the study period or for 28 days after study drug discontinuation. No sperm donation is allowed during the study period and for 92 days after study drug discontinuation
  4. illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing
  5. Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; example, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system
  6. Any history of surgery that may affect pharmacokinetic (PK) profiles of E2086, example, hepatectomy, nephrotomy, digestive organ resection or participants who have a congenital abnormality in metabolism
  7. Any clinically abnormal symptom or organ impairment found by medical history at screening, and physical examinations, vital signs, finding, or laboratory test results that require medical treatment at screening or baseline
  8. Evidence of clinically significant disease (example, cardiac, respiratory, gastrointestinal, renal disease, sleep disorders) that in the opinion of the investigators could affect the participant's safety or interfere with the study assessments
  9. A prolonged /QTc interval (QTcF greater than [>] 450 milliseconds [ms]) demonstrated on ECG at screening or baseline (based on average of triplicate ECGs). A history of risk factors for torsade de pointes (example, heart failure, hypokalemia, family history of long QT Syndrome) or the use of concomitant medications that prolonged the QT/QTc interval
  10. Left bundle branch block at screening or baseline
  11. Persistent systolic blood pressure (BP) >130 or \<100 millimeters of mercury (mmHg) or diastolic BP >85 or \<50 mmHg at screening or baseline (based on BP measured on at least 3 occasions over 2 weeks)
  12. Persistent heart rate (HR) \<50 bpm or >100 bpm at screening or baseline (based on HR measured on at least 3 occasions over 2 weeks)
  13. History of myocardial infarction, ischemic heart disease, or cardiac failure
  14. History of clinically significant arrhythmia or uncontrolled arrhythmia
  15. Any lifetime history of suicidal ideation or any lifetime history of suicidal behavior as indicated by the C-SSRS
  16. Any lifetime history of psychiatric disease (including but not limited to depression or other mood disorders, bipolar disorder, psychotic disorders, including schizophrenia, panic attacks, anxiety disorders)
  17. Any current psychiatric symptoms as indicated by a standard screening tool ( Self-Rated Level 1 Cross-Cutting Symptom Measure - Adult)
  18. Participants with 1 or more first degree (blood) relatives who have lifetime diagnosis of bipolar type I disorder or a psychotic disorder
  19. Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or donation of plasma within 1 week of dosing
  20. History of formally diagnosed moderate to severe obstructive sleep apnea, current use of continuous positive airway pressure, or symptomatic restless legs syndrome
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Part A, Cohort 1: E2086 Dose 1 or Placebo

    Healthy participants will receive E2086 Dose 1 or two E2086 matched placebo, tablets, orally, once daily after an overnight fast of 10 hours.

    Drug: E2086 · Drug: Placebo

  • Experimental
    Part A, Cohort 2: E2086 Dose 2 or Placebo

    Healthy participants will receive E2086 Dose 2 or one E2086 matched placebo, tablets, orally, once daily after an overnight fast of 10 hours.

    Drug: E2086 · Drug: Placebo

  • Experimental
    Part A, Cohort 3: E2086 Dose 3 or Placebo

    Healthy participants will receive E2086 Dose 3 or two E2086 matched placebo, tablets, orally, once daily after an overnight fast of 10 hours.

    Drug: E2086 · Drug: Placebo

  • Experimental
    Part B: E2086 Dose 2 Fasted + E2086 Dose 2 Fed

    Healthy participants will receive E2086 Dose 2, tablets, orally, once on Day 1 of Treatment Period 1 in fasted state, followed by E2086 Dose 2, tablets, orally, once on Day 4 of Treatment Period 2 in fed state.

    Drug: E2086

  • Experimental
    Part B: E2086 Dose 2 Fed + E2086 Dose 2 Fasted

    Healthy participants will receive E2086 Dose 2, tablets, orally, once on Day 1 of Treatment Period 1 in fed state, followed by E2086 Dose 2, tablets, orally, once on Day 4 of Treatment Period 2 in fasted state.

    Drug: E2086

Interventions

  • DrugE2086

    E2086 tablets.

  • DrugPlacebo

    E2086 matched placebo tablets.

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Day 10

  2. Part A: Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Day 10

  3. Part A: Number of Participants With Clinically Significant Abnormal Laboratory Parameters

    Time frame: Day 10

  4. Part A: Number of Participants With Clinically Significant Abnormal Vital Signs Values

    Time frame: Day 10

  5. Part A: Number of Participants With Clinically Significant Abnormal Electrocardiograms (ECGs) Findings

    Time frame: Day 10

  6. Part A: Number of Participants With Clinically Significant Abnormal Electroencephalogram (EEG) Findings

    Time frame: Day 8

  7. Part A: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is an interview-based rating scale to systematically assess any suicidality, suicidal behavior, or suicidal ideation. Any suicidality is emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior is indicated when response is "yes" for any these questions- actual attempt to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation is indicated when response is "yes" for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide.

    Time frame: Day 10

  8. Part B: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS

    The C-SSRS is an interview-based rating scale to systematically assess any suicidality, suicidal behavior, or suicidal ideation. Any suicidality is emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior is indicated when response is "yes" for any these questions- actual attempt to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation is indicated when response is "yes" for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide.

    Time frame: Day 7

Secondary outcomes

  1. Part A, Cmax: Maximum Observed Plasma Concentration of E2086 and its Metabolite M1

    Time frame: Day 1 and at steady-state

  2. Part A, Tmax: Time to Reach Maximum Observed Plasma Concentration (Cmax) of E2086 and its Metabolite M1

    Time frame: Day 1 and at steady-state

  3. Part A, Css: Average Steady State Concentration of E2086 and its Metabolite M1

    Time frame: Day 1 and at steady-state

  4. Part A, AUC(0-24h): Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Post-dose of E2086 and its Metabolite M1

    Time frame: Day 1

  5. Part A, t1/2: Terminal Elimination Phase Half-life of E2086 and its Metabolite M1

    Time frame: Day 1 and at steady-state

  6. Part A, Rac (Cmax): Accumulation Ratio for Cmax of E2086 and its Metabolite M1

    Time frame: Day 1 and at steady-state

  7. Part A, Rac (AUC0-24h): Accumulation Ratio for AUC0-24 Hours of E2086 and its Metabolite M1

    Time frame: Day 1

  8. Part A, Ae: Cumulative Amount of E2086 and its Metabolite M1 Excreted in Urine

    Time frame: At steady-state

  9. Part A, CLR: Renal Clearance of E2086 and its Metabolite M1

    Time frame: At steady-state

  10. Part A, Fe: Fraction of E2086 and its Metabolite M1 Excreted in Urine

    Time frame: At steady-state

  11. Part A, MRU: Ratio of Cumulative Amount of Metabolite M1 to E2086 Excreted in Urine Concentration

    Time frame: At steady-state

  12. Part A: Geometric Mean Ratio of Cmax Between Healthy Non-Japanese and Japanese Participants After Administration of E2086

    Time frame: Day 1 and at steady-state

  13. Part A: Geometric Mean Ratio of AUC0-24 Hour Between Healthy Non-Japanese and Japanese Participants After Administration of E2086

    Time frame: Day 1

  14. Part B: Geometric Mean Ratio of Cmax Between the Fasted and Fed State for Single Dose of E2086 Dose 2

    Time frame: After single doses in Fasted and Fed State

  15. Part B: Geometric Mean Ratio of Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Between the Fasted and Fed State for Single Dose of E2086 Dose 2

    Time frame: After single doses in Fasted and Fed State

  16. Part B: Geometric Mean Ratio of Area Under the Plasma Concentration-time Curve From Time Zero to Infinite (AUC0-inf) Between the Fasted and Fed State for Single Dose of E2086 Dose 2

    Time frame: After single doses in Fasted and Fed State

  17. Part A: Change From Baseline in QTc Using the Fridericia Formula (QTcF) From Holter ECG

    A central ECG laboratory will extract ECG recordings from the Holter device.

    Time frame: Baseline to Day 8

  18. Part A: Placebo Corrected Change From Baseline in QTcF Using Holter ECG

    A central ECG laboratory will extract ECG recordings from the Holter device.

    Time frame: Baseline to Day 8

  19. Part A: Change From Baseline in Subjective Sleep Onset Latency (sSOL)

    sSOL is a participant-reported parameter. Sleep onset latency is a measure of how long it takes for the participant to fall asleep once the participant gets into bed. This will be measured in minutes.

    Time frame: Baseline to Day 10

07

Study locations

1 site
  • Parexel International
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Dec 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2024
First posted
Jul 1, 2024
StartActual
Jun 25, 2024
Primary completionActual
Dec 13, 2024
CompletionActual
Dec 13, 2024
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06481488
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jul 1, 2024
Start date
Jun 25, 2024
Primary completion
Dec 13, 2024
Completion
Dec 13, 2024
Last update
Jan 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ledasorexton

Start the discussion